顶部联系方式

Time of issue:2018-03-12 00:00:00

Have Any Questions?  Mabspace BiosciencesInfo@mabspacebio.com 迈博斯生物0512-86861701

搜索
迈博斯生物

语言切换

Time of issue:2019-11-21 00:00:00
这是描述信息

NEWS

>>
>>
good news! Maibos Bio announces that its world's first pH-dependent PD-L1 antibody has obtained Chinese clinical approval

good news! Maibos Bio announces that its world's first pH-dependent PD-L1 antibody has obtained Chinese clinical approval

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:56
  • Views:

(Summary description)On June 6, 2018, Suzhou, China, Maibos Bio announced today that the company's independently developed world-first pH-dependent PD-L1 antibody MSB2311 has officially obtained the drug clinical trial ap

good news! Maibos Bio announces that its world's first pH-dependent PD-L1 antibody has obtained Chinese clinical approval

(Summary description)On June 6, 2018, Suzhou, China, Maibos Bio announced today that the company's independently developed world-first pH-dependent PD-L1 antibody MSB2311 has officially obtained the drug clinical trial ap

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:56
  • Views:
Information

On June 6, 2018, Suzhou, China, Maibos Bio announced today that the company's independently developed world-first pH-dependent PD-L1 antibody MSB2311 has officially obtained the drug clinical trial approval (approval) issued by the State Food and Drug Administration. No. 2018L02471) This is another major development of Maibos Bio following the FDA clinical approval of this product in February this year.

 

Dr. Xueming Qian, the founder, chairman and CEO of Maibos Bio said, "The acquisition of MSB2311 China clinical approval is an important milestone in the development of Maibos Bio. It is the crystallization of the sincere cooperation of Maibos Bio team. This approval allows us to quickly start clinical trials in China, synchronize development with the ongoing Phase I clinical trials in the United States, and make the commercial development strategy of MSB2311 more flexible and international. "

 

About MSB2311

 

MSB2311 is the second generation of humanized therapeutic PD-L1 antibody developed by Maibos Bio through its unique immune tolerance barrier breakthrough technology (IMBTTM). Different from the epitopes bound by existing PD-L1 antibodies approved for marketing abroad, the binding of this antibody to PD-L1 has a unique pH dependence, which is conducive to the recovery and penetration of antibodies in tumor tissues. In vivo experiments show that at the same dose, the product has higher drug concentration in the tumor, longer drug retention time, and better efficacy in animal models. During the product development process, the product also showed excellent CMC characteristics.

 

Maibosi Biological will make every effort to promote the domestic and international marketing process of the MSB2311 project, provide affordable antibody drugs for the quality and quantity of patients, and work hard to protect the health and safety of patients.

 

About Maibos Bio

 

Maibosi Biomedicine (Suzhou) Co., Ltd. is a biotechnology company focusing on research and development of innovative antibody drugs. Headquartered in Suzhou, the company has complete antibody drug discovery and development facilities in the Suzhou Industrial Park BioBAY Industrial Park (BioBAY). With its unique immune tolerance barrier breakthrough technology (IMBTTM), it has established more than 10 product lines focusing on tumor treatment. For more information, please visit Maibos website: www.mabspacebio.com

Kathy YUAN

Email: kathy.yuan@mabspacebio.com

Tel: + 86-512-67079200

Scan the QR code to read on your phone

页脚关于我们

Time of issue:2019-11-23 00:00:00

页脚管道

Time of issue:2019-11-23 00:00:00

页脚新闻

Time of issue:2019-11-23 00:00:00

页脚人力资源

Time of issue:2019-11-23 00:00:00

页脚联系方式

Time of issue:2019-11-23 00:00:00

页脚版权

Time of issue:2019-11-23 00:00:00

Copyright © 2019 Mabspace Biosciences All rights reserved

页脚备案

Time of issue:2019-11-23 00:00:00